From Science Push to Market Pull

“Dreavent led our Series C, financing Elicio in a historically difficult biotech financing era, working with us for a full year-plus relentlessly, over several closes.

Since the Series C closed in 2022 Dreavent has been incredibly supportive and resourceful, making connections with other investors and potential business development partners.

They are incredibly responsive, creative, with great sense of urgency, and worldwide networks. I've been a CEO for 24 years and I have never worked with an investor who was so invested in the success of my company, with a "whatever it takes" mentality. It feels very much like they are on the team, not just an investor- true believers. They are also just good people which makes working through the tough issues SO much easier. I could not recommend anyone more highly."

"Therini Bio is thrilled to have Dreavent join our Series A financing. After taking time to thoughtfully get to know the management team and our plans, Dreavent fully committed to Therini's long-term vision for developing fibrin-targeting therapeutics intended to halt neuroinflammation in diseases including neurodegenerative and retinal diseases.

The diligence process was efficient, with clear communication and high degree of transparency from the Dreavent team. They are also understanding about changes that inevitably arise in an early stage company like ours. Gorka has already become a strong supporter and trusted partner to Therini, making helpful introductions for the company through his broad investor network.

We appreciate Dreavent's investment and continued support!"

"Dreavent has been a very supportive investor in Inspirna since 2022. Their diligence process was straightforward and efficient, and they are transparent throughout. Dreavent's long term focus was helpful as Inspirna seeks to tackle difficult problems in cancer metastasis and progression.

Our company is pleased to count Dreavent as an institutional investor and we look forward to continuing to work with Gorka Fius and Bill Korinek as Inspirna seeks to bring new first-in-class cancer medicines to patients."

"Having raised a venture capital fund and invested in early stage life science companies as a venture capitalist and now leading an innovative, next- generation mRNA company, as CEO, I recognize how important having a committed, talented venture team like Dreavent is to the success of companies like Chimeron Bio.

Capital is an essential ingredient, but multifold more impactful when underpinned by the vision, expertise and non- financial resources that Dreavent brings with its investment."

"As CEO of Aardvark Therapeutics, Inc., I would like to convey gratitude and appreciation for the support and steady conviction of Dreavent. Since their investment into Aardvark's Series B, it was clear that the Dreavent team was driven by a rational long- term approach vs only a quick incremental win.

Importantly, Dreavent has been continually supportive in ways beyond their investment, leveraging their extensive network and making strategic introductions whenever the opportunity arose. It has been a pleasure and a positive experience working with Dreavent.

Moreover, recognizing the significant contributions Dreavent has made to our company's growth and success, we were thrilled to have them participate in our Series C round which was substantially oversubscribed.""

"I'm doing everything that I did before my diagnosis can do anything that want. I can walk long distances; I can swim and I can ride my bike again"

"Working with this team has proven their reliability in decision-making. They consistently demonstrate thorough analysis and a deep understanding of the investment landscape, which has significantly contributed to our success. Their expertise and solid judgment have made them invaluable partners."